Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00003153
Other study ID # CDR0000065938
Secondary ID ECOG-E1A97
Status Completed
Phase Phase 2
First received
Last updated
Start date July 22, 1998
Est. completion date May 1, 2009

Study information

Verified date June 2023
Source Eastern Cooperative Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving donor white blood cells works in treating patients with recurrent multiple myeloma who have undergone bone marrow transplantation.


Description:

OBJECTIVES: - Assess the response rate of patients with recurrent multiple myeloma after an allogeneic marrow transplant from a genotypically HLA identical sibling donor treated with donor lymphocyte infusions as salvage therapy . - Evaluate the safety and toxicity of this treatment when used as salvage therapy in these patients. OUTLINE: Patients receive initial cell dose of donor lymphocytes (CD3+ cells) IV over 15-30 minutes. Patients with rapidly progressive disease may skip the initial cell dose and proceed directly to dose escalation to receive CD3+ cells at a higher cell dose. Patients who achieve complete response to the initial treatment may receive up to 2 additional courses of escalating doses of CD3+ cells 8-12 weeks apart in the absence of unacceptable toxicity. Patients are evaluated at 4 and 8 weeks after each infusion. Patients with disease progression at 8 weeks are retreated at that time. Patients who achieve partial response or stable disease at 8 weeks are re-evaluated at 12 weeks and may then be retreated. Patients are followed every 2 weeks for 3 months, once a month for 9 months, and then every 2 months thereafter. PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study within 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date May 1, 2009
Est. primary completion date February 2007
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS: - Histologically confirmed recurrent or persistent multiple myeloma at least 6 months following allogeneic bone marrow transplantation (BMT) from an HLA identical sibling - Must meet one of following criteria to be considered persistent, recurrent, or progressive disease: - Residual detectable disease 6-12 months after BMT, as determined by the M protein level or bone marrow involvement, without further evidence of clinical or laboratory improvement on 2 consecutive measurements 4 weeks apart - Complete response not achieved 12 or more months after BMT and there is no evidence of progressive improvement - At least 25% increase of serum paraprotein (greater than 1.0 g/dL) as measured on two occasions or a 50% increase in urinary light chain excretion (greater than 150 mg/day) as measured on 2 occasions - A 10% increase in plasma cells in the bone marrow - Disease in complete response but with recurrence of M protein and 10% point increase in myeloma cells in the marrow allowed - No lytic lesions alone or new soft tissue plasmacytoma as sole evidence of progression PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - More than 4 weeks Hematopoietic: - Not specified Hepatic: - Bilirubin no greater than 2.0 times upper limit of normal Renal: - Not specified Other: - No active infection - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Must have received prior allogeneic bone marrow transplantation from an HLA A;B;DR genotypically matched sibling donor - No concurrent interferon therapy for relapsed disease Chemotherapy: - At least 4 weeks since cyclosporine, methotrexate, azathioprine, or other graft versus host disease (GVHD) prophylaxis/treatment without evidence of flare of GVHD - At least 4 weeks since prior chemotherapy for relapsed disease Endocrine therapy: - Must be receiving a dose no greater than 0.25 mg/kg prednisone for at least 4 weeks prior to registration without flare of GVHD - No prior prednisone dose greater than 0.25 mg/kg in the past 4 weeks - Must receive concurrent prednisone of a dose no greater than 0.25 mg/kg - Concurrent corticosteroids allowed Radiotherapy: - Concurrent palliative radiotherapy allowed if evidence of other evaluable disease other than irradiated bony sites Surgery: - Not specified

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
therapeutic allogeneic lymphocytes


Locations

Country Name City State
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Medical College of Wisconsin Cancer Center Milwaukee Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
Eastern Cooperative Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM, Huff CA; ECOG Myeloma and BMT Committees. A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97. Biol Blood Marrow Transplant. 2009 Jan;15(1):83-91. doi: 10.1016/j.bbmt.2008.10.030. Erratum In: Biol Blood Marrow Transplant. 2009 Oct;15(10):1346. Huff, Carol A [added]. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT00568880 - Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT01137825 - Registry of Older Patients With Cancer
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00313625 - Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00478075 - Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT00608517 - Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil N/A
Completed NCT00898066 - S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease N/A
Completed NCT00951626 - A Standardized Nursing Intervention Protocol for HCT Patients N/A
Completed NCT00301951 - Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer Phase 1
Terminated NCT00369291 - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Phase 1
Completed NCT00937183 - Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma N/A
Completed NCT00049374 - Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Phase 2
Completed NCT00004072 - O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00003399 - Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma Phase 2
Completed NCT00003396 - Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Phase 2
Completed NCT00003398 - Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Phase 4
Active, not recruiting NCT00003163 - Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Phase 2
Terminated NCT00005641 - Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation Phase 2
Active, not recruiting NCT00002599 - Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Phase 3